Inclusion Criteria:~1. Age of ≥50 to ≤85 as of the date of informed consent~2. Clinical diagnosis of probable
Alzheimer's disease according to Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV) and
National Institute of Neurological and Communicative Disorders and Strokes; Alzheimer's disease and Related
Disorders Association (NINCDS-ADRDA)~3. Mini Mental Status Examination (MMSE) score ≥10 to ≤26 at screening~4.
Global Clinical Dementia Rating (CDR) score 0.5, 1 or 2 at screening~5. Capable of performing procedures for
cognitive and other tests~6. Subject who meets any of the following as of the date of informed consent~ * No
past treatment with donepezil (naÃ¯ve patient)~ * Ongoing treatment with donepezil 10mg/day for the past 3
months~ * Ongoing treatment with donepezil 5mg/day for the past 3 months~7. The subject or his/her
representative must voluntarily decide to participate in the study and provide written informed consent.~8. The
subject must have a reliable caregiver who regularly contacts the subject and is available to accompany the
subject for on-site visits. (Note: A caregiver is defined as someone who has regular contact with the subject
\[i.e., an average of approximately 10 or more hours per week\], must be able to oversee subject's compliance
with the study treatment and to report on the patient's status and must be able to accompany the subject to all
study visits.)~
